Scholarlink

Introduction <p>For some patients with plaque psoriasis (PsO), a rapid response (i.e. short interval to time to onset of action [TOA]) is desired. The primary objective was to determine average time to achieve a Psoriasis Area and Severity Index (PASI)&#xa0;90 response (50% of patients) for individual biologics or targeted therapies. Secondary outcomes included the average time to achieve a PASI&#xa0;75 response (50% of patients), as well as PASI&#xa0;90 and PASI&#xa0;75 responses over the first 16&#xa0;weeks of therapy.</p> Methods <p>A systematic targeted literature review was conducted to identify phase&#xa0;III and IV randomised, double-blinded trials according to pre-specified eligibility criteria that investigated interleukin (IL)-12/23 inhibitors, IL-17 inhibitors, IL-23 inhibitors, Janus kinase (JAK) inhibitors, and phosphodiesterase (PDE) inhibitors. Using proportions of patients achieving PASI&#xa0;90 or 75 responses over 16&#xa0;weeks, network meta-analyses were conducted to estimate response over time. This was presented as curves, and TOA was summarized as median time to reach the 50th percentile.</p> Results <p>Forty-five trials were included in the main analyses. The IL-17 inhibitors bimekizumab, ixekizumab, brodalumab, and secukinumab 300&#xa0;mg were estimated to provide the earliest onset of PASI&#xa0;90 response at approximately 6 to 8&#xa0;weeks. This was followed by the IL-23 inhibitors risankizumab and guselkumab at approximately 9–10&#xa0;weeks, and the IL-12/23 inhibitor at 11–12&#xa0;weeks. Although wide and overlapping credible intervals and similar point estimates were observed, these results suggest onset of action does not vary greatly across biologics in these classes. Onset of PASI&#xa0;90 response could not be estimated by the model for tildrakizumab, and JAK and PDE4 inhibitors. Onset of PASI&#xa0;75 response showed similar trends to PASI&#xa0;90 response.</p> Conclusions <p>IL-17 inhibitors, followed by IL-23 inhibitors, have the most rapid TOA among PsO biologics evaluated; any differences in onset of action between specific agents within the same drug class are not statistically or clinically significant. These analyses will allow clinicians to make more informed treatment decisions for their patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-Analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月17日

查看全文
  • Kim A. Papp,
  • Ron Vender,
  • Kerri Purdy,
  • Fiona Lovegrove,
  • Irina Oroz,
  • Parbeer Grewal,
  • Perla Lansang,
  • Laura Park-Wyllie,
  • Nastaran Abbarin,
  • Ya-Wen Yang,
  • Becky Hooper,
  • Sandra Vigelis,
  • Tim Disher,
  • Richard G. Langley

摘要

Introduction

For some patients with plaque psoriasis (PsO), a rapid response (i.e. short interval to time to onset of action [TOA]) is desired. The primary objective was to determine average time to achieve a Psoriasis Area and Severity Index (PASI) 90 response (50% of patients) for individual biologics or targeted therapies. Secondary outcomes included the average time to achieve a PASI 75 response (50% of patients), as well as PASI 90 and PASI 75 responses over the first 16 weeks of therapy.

Methods

A systematic targeted literature review was conducted to identify phase III and IV randomised, double-blinded trials according to pre-specified eligibility criteria that investigated interleukin (IL)-12/23 inhibitors, IL-17 inhibitors, IL-23 inhibitors, Janus kinase (JAK) inhibitors, and phosphodiesterase (PDE) inhibitors. Using proportions of patients achieving PASI 90 or 75 responses over 16 weeks, network meta-analyses were conducted to estimate response over time. This was presented as curves, and TOA was summarized as median time to reach the 50th percentile.

Results

Forty-five trials were included in the main analyses. The IL-17 inhibitors bimekizumab, ixekizumab, brodalumab, and secukinumab 300 mg were estimated to provide the earliest onset of PASI 90 response at approximately 6 to 8 weeks. This was followed by the IL-23 inhibitors risankizumab and guselkumab at approximately 9–10 weeks, and the IL-12/23 inhibitor at 11–12 weeks. Although wide and overlapping credible intervals and similar point estimates were observed, these results suggest onset of action does not vary greatly across biologics in these classes. Onset of PASI 90 response could not be estimated by the model for tildrakizumab, and JAK and PDE4 inhibitors. Onset of PASI 75 response showed similar trends to PASI 90 response.

Conclusions

IL-17 inhibitors, followed by IL-23 inhibitors, have the most rapid TOA among PsO biologics evaluated; any differences in onset of action between specific agents within the same drug class are not statistically or clinically significant. These analyses will allow clinicians to make more informed treatment decisions for their patients.